Craig-Hallum lowered the firm’s price target on Akoya Biosciences to $7 from $7.50 and keeps a Buy rating on the shares. While the significant sequential improvement shown in Q2 reinforces the firm’s view that the Q1 results were indeed an anomaly, Craig-Hallum also comes away from Q2 with a more muted view of pace of revenue recovery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKYA:
- AKYA Upcoming Earnings Report: What to Expect?
- Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
- Craig-Hallum starts Akoya with a Buy, says shares ‘significantly’ undervalued
- Akoya Biosciences initiated with a Buy at Craig-Hallum
- Akoya Biosciences management to meet virtually with BTIG